Currently, there are 428.02M common shares owned by the public and among those 361.50M shares have been available to trade.
The company’s stock has a 5-day price change of -5.74% and 35.36% over the past three months. XP shares are trading -0.60% year to date (YTD), with the 12-month market performance up to 53.76% higher. It has a 12-month low price of $10.82 and touched a high of $20.64 over the same period. XP has an average intraday trading volume of 6.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.79%, -3.75%, and 15.06% respectively.
Institutional ownership of XP Inc (NASDAQ: XP) shares accounts for 59.21% of the company’s 428.02M shares outstanding.
It has a market capitalization of $9.60B and a beta (3y monthly) value of 1.15. The stock’s trailing 12-month PE ratio is 11.78, while the earnings-per-share (ttm) stands at $1.55. The company has a PEG of 1.08 and a Quick Ratio of 0.18 with the debt-to-equity ratio at 3.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.14% over the week and 2.03% over the month.
Analysts forecast that XP Inc (XP) will achieve an EPS of 2.36 for the current quarter, 2.38 for the next quarter and 10.73 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 2.33 while analysts give the company a high EPS estimate of 2.33. Comparatively, EPS for the current quarter was 2.03 a year ago. Earnings per share for the fiscal year are expected to increase by 5.61%, and 15.21% over the next financial year. EPS should shrink at an annualized rate of 10.88% over the next five years, compared to 23.61% over the past 5-year period.
Looking at the support for the XP, a number of firms have released research notes about the stock. Itau BBA stated their Market Perform rating for the stock in a research note on June 23, 2025, with the firm’s price target at $21. Goldman coverage for the XP Inc (XP) stock in a research note released on June 04, 2025 offered a Buy rating with a price target of $23. Morgan Stanley was of a view on May 13, 2025 that the stock is Overweight, while Itau BBA gave the stock Outperform rating on March 18, 2025, issuing a price target of $20. UBS on their part issued Buy rating on January 24, 2025.
